european medicines agency glp-1 vision loss recommendation november 2025 In the phase 3 ACHIEVE-1 trial, published in June 2025, the oral small-molecule receptor agonist orforglipron significantly reduced the glycated hemoglobin level over a period of 40 weeks in adults with European regulators want to know

8, 2025 FAYETTEVILLE, Ark

This pricing dynamic constrains overall market penetration and slows adoption despite the strong clinical benefits of GLP-1 therapies in weight management and glycemic control, making cost a key obstacle to broader global uptake

Cytoplasmic recruitment of Mdm2 as a common characteristic of G protein-coupled receptors that undergo desensitization

When CPT1C is upregulated, it increases FA consumption, and ATP production, facilitating tumor growth and survival 43

Ergonomic Adjustments Sometimes, neck pain can result from poor posture or an unsupportive work environment

Materials 14 (12), 3332 (2021)